Keytruda, Opdivo Set To Challenge Tecentriq In Bladder Cancer

21 Oct 2016

• By Emily Hayes

Phase III trial of Merck's Keytruda stops early with survival benefit as FDA accepts filing of Bristol's Opdivo, which has breakthrough therapy status and priority review.

The days may be numbered for Roche's Tecentriq as the only programmed death inhibitor in the market for bladder cancer following FDA’s acceptance of a filing for Bristol-Myers Squibb Co.'s Opdivo and positive Phase III data in the KEYNOTE-045 study of Merck & Co. Inc.'s Keytruda.

Merck announced Oct. 21 that the KEYNOTE-045 study of its PD-1 inhibitor Keytruda (pembrolizumab) in 542 patients with previously treated advanced urothelial cancer was being terminated early because the drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

02 Jun 2025

• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

02 Jun 2025

• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

02 Jun 2025

• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.